Trial-matching tools read structured fields and sometimes the free-text note to list studies a patient might qualify for. Tempus, Flatiron, and Deep 6 AI are examples of companies that sell a version of this. A research coordinator still checks every criterion against the chart. A match list is not enrollment, and it is not a treatment recommendation.
Clinical setting
Oncology clinics and trial offices that already have a coordinator, using the match list to decide whom to screen by hand.
Tools and vendors
Tempus
Flatiron
Deep 6 AI
What was reported
No enrollment-rate or speed figure is repeated here. Those claims are vendor-specific and often omit how many suggestions a coordinator rejects.
Insilico Medicine used a generative platform to propose TNIK as a target in idiopathic pulmonary fibrosis and to design rentosertib (formerly ISM001-055). Nature Medicine published a 12-week randomized phase 2a trial in 2025. The primary endpoint was safety, not lung function. The molecule is investigational. A small secondary signal is not an approved therapy.
Pharma.AI · Insilico Medicine · rentosertib (ISM001-055)
The Targeted Real-time Early Warning System (TREWS) watches the electronic record and asks a clinician to confirm or dismiss a possible sepsis alert. It was studied prospectively across five hospitals, not as a silent background score. The published association depends on a person acting on the alert within a few hours. It does not diagnose sepsis by itself.
This is an illustrative composite, not a trial report. A unit feeds monitor alarms through a second layer that withholds repeats already explained by motion, a loose lead, or a value the nurse just acknowledged. The bedside alarm for a new life-threatening rhythm still sounds. The point of the scenario is the governance question: who is allowed to silence what, and how a missed true alarm would be reviewed.